



FOR IMMEDIATE RELEASE

DermTech, Inc. Announces Financing Milestone

La Jolla, December 31, 2015 – DermTech, Inc., an emerging diagnostics company focusing on skin cancers, announced today that it has reached a financing milestone surpassing \$5.0 million in new equity raised.

Steve Kemper, the company's CFO, stated: "we are very pleased with the reception to our Common Unit offering from new investors and with the efforts provided by our placement agent. The achievement of reaching \$5 million in new equity allows us to continue with our commercial expansion including the hiring of new sales rep's, the launch of our co-marketing efforts with Quest Diagnostics and the continued scaling of our CLIA laboratory operations and related support activities."

ABOUT DermTech

DermTech is a commercial stage molecular dermatology company developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. DermTech operates a CLIA licensed laboratory located in the company's La Jolla, CA headquarters. DermTech's technology allows the analysis of skin biopsy samples collected *non-invasively* using an adhesive patch. DermTech provides highly accurate, objective information to the physicians to improve care and reduce costs. Current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. For additional information visit: www.dermtech.com.

Contacts

DermTech, Inc.
Sarah Dennison, MBA
VP of Marketing
(858) 450-4222
sdennison@dermtech.com